Otenzepad

Drug From Wikipedia, the free encyclopedia

Otenzepad is a competitive muscarinic receptor antagonist that is relatively selective at the M2 receptor. It was investigated as a treatment for arrhythmia and bradycardia due to its cardioselectivity but research ceased after stage III clinical trials. The drug was originally developed by the German pharmaceutical company, Boehringer Ingelheim Pharma KG.[1]

CAS Number
Quick facts Clinical data, Routes ofadministration ...
Otenzepad
Structure of Otenzepad
Clinical data
Routes of
administration
oral
Pharmacokinetic data
Bioavailability45% (oral)[1]
Elimination half-life2.5h
Identifiers
  • 11-[2-[2-(diethylaminomethyl)piperidin-1-yl]acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.220.541 Edit this at Wikidata
Chemical and physical data
FormulaC24H31N5O2
Molar mass421.545 g·mol−1
3D model (JSmol)
  • CCN(CC)CC1CCCCN1CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
  • InChI=1S/C24H31N5O2/c1-3-27(4-2)16-18-10-7-8-15-28(18)17-22(30)29-21-13-6-5-11-19(21)24(31)26-20-12-9-14-25-23(20)29/h5-6,9,11-14,18H,3-4,7-8,10,15-17H2,1-2H3,(H,26,31)
  • Key:UBRKDAVQCKZSPO-UHFFFAOYSA-N
Close

Pharmacodynamics

The (+)-enantiomer has 8 times greater potency at the M2 receptor than the (-)-enantiomer.[1]

More information mAChR isoform, Dissociation constant (Ki) ...
Potency of Otenzepad at muscarinic receptor isoforms[1]
mAChR isoform Dissociation constant (Ki)
M1 537.0 - 1300nM[1][2]
M2 81.0 - 186nM[1][2]
M3 838 - 2089.0nM[2][1]
M4 407.0 - 1800nM[1][2]
M5 2800nM[2]
Close


See also

References

Related Articles

Wikiwand AI